Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Jun 22.
doi: 10.1007/s11030-025-11259-7. Online ahead of print.

Design, synthesis and antitumor activity of thiadiazole derivatives as novel ALK kinase inhibitors

Yiwen Huo #  1 , Qinjiang Zhou #  1 , Cheng Zhang #  1 , Yanna Lv #  1 , Rongfei Liu  1 , Mingyue Hou  1 , Xiaoxuan Duan  1 , Yue Liu  2 , Jinxing Hu  3
Affiliations

Design, synthesis and antitumor activity of thiadiazole derivatives as novel ALK kinase inhibitors

Yiwen Huo et al. Mol Divers. .

Abstract

In recent years, the number of patients with ALK-positive NSCLC has increased, along with the emergence of various resistance mutations. To address the resistance issues caused by ALK mutations, this study used Crizotinib as the lead compound and modified its side chain to design and synthesize a series of compounds containing thiadiazole structures. The compounds were evaluated through tyrosine kinase inhibition assays and cellular experiments. The results show that compound B11 exhibits strong cytotoxic activity against the NSCLC NCI-H2228 cell line. Moreover, B11 demonstrates a dose-dependent effect, inhibiting NCI-H2228 cell viability, inducing G0/G1-phase cell cycle arrest, and promoting cell death. More importantly, compound B11 overcomes the resistance caused by the ALKG1202R mutation. Ultimately, compound B11, which contains a thiadiazole structure, shows promising activity (ALKL1196M IC50 = 5.57 nM; ALKwt IC50 = 9.19 nM; ALKG1202R IC50 = 15.6 nM).

Keywords: ALK; ALKG1202R; Antitumor; NSCLC; Thiadiazole.

PubMed Disclaimer

Conflict of interest statement

Declarations. Conflict of interest: The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

References

    1. Li Z, Guo M, Cao M, Zhao T, Li M, Zhai X (2021) Discovery and antitumor activity of Benzo[d]imidazol-containing 2,4-diarylaminopyrimidine analogues as ALK inhibitors with mutation-combating effects. Bioorgan Med Chem 37:116108 - DOI
    1. Asati V, Ayaz MS, Bhupal R, Sharma P, Sahu A, Singh P, Gupta GD (2023) Recent updates on structural aspects of ALK inhibitors as an anticancer agent, anti-cancer agents. Med Chem 23:900–921
    1. Gou W, Li Z, Xu X, Shen J, Guo M, Zhou X, Zhang X, Wu Y, Zhai X, Zuo D (2020) ZX-29, a novel ALK inhibitor, induces apoptosis via ER stress in ALK rearrangement NSCLC cells and overcomes cell resistance caused by an ALK mutation. BBA-Mol Cell Res 1867:118712
    1. Ren J, Gao Y, Shi W, Xu S, Wang Q, Zhao D, Kong L, Song W, Wang X, Zhang Y, He X, Wang Y, Tong S, Lu P, Li Y, Xu H, Zhang Y (2022) Design and synthesis of boron-containing ALK inhibitor with favorable in vivo efficacy. Bioorgan Med Chem 75:117071 - DOI
    1. Shaw AT, Engelman JA (2013) ALK in lung cancer: past, present, and future. J Clin Oncol 31:1105–1111 - DOI - PubMed - PMC

LinkOut - more resources